DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia

Phase 1

Active, not recruiting

• Conditions: Adductor Spasmodic Dysphonia; Voice Disorders; Spasmodic Dysphonia

• Registration Number: NCT05158166
• Lead Sponsor: University of California, San Francisco

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-11-19
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Inclusion Criteria:<br><br> - greater than 18<br><br> - diagnosis of adductor spasmodic dysphonia<br><br> - previous successful treatment with BotoxA<br><br> - stabilized dose for last 3 treatments<br><br>Exclusion Criteria:<br><br> - age less than 18<br><br> - exclusively having other neurologic conditions such as:<br><br> - abductor spasmodic dysphonia<br><br> - ALS<br><br> - Multiple sclerosis<br><br> - Parkinson's disease<br><br> - Essential tremor

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Our primary outcome is the difference in VHI-10 score at 6 weeks after injection with DAXI.

Secondary Outcome Measures

Name	Time	Method
A secondary outcome will be comparing the duration of effect of DAXI with patients' prior Botox treatment.